Atea Pharmaceuticals
AVIR
125 hedge funds and large institutions have $276M invested in Atea Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 38 reducing their positions, and 20 closing their positions.
9,700% more call options, than puts
Call options by funds: $98K | Put options by funds: $1K
21% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 38
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
1.16% less ownership
Funds ownership: 75.43% → 74.27% (-1.2%)
2% less funds holding
Funds holding: 127 → 125 (-2)
14% less capital invested
Capital invested by funds: $323M → $276M (-$46.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.25M |
| 2 |
BlackRock
New York
|
+$1.42M |
| 3 |
QCM
Quantinno Capital Management
New York
|
+$1.13M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.05M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$2.25M |
| 2 |
Two Sigma Investments
New York
|
-$1.78M |
| 3 |
ICM
Irenic Capital Management
New York
|
-$1.62M |
| 4 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$1.44M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$1.42M |
AVIR Hedge Fund Activity: Q2 2026 in Review
125 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q2 2026, worth a combined $276M — down 14% from $323M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of AVIR and 19 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 46 added.
The largest buyer was Acadian Asset Management, adding an estimated $2.25M. The largest seller was Jane Street, exiting entirely with an estimated $2.25M sold.
- 125 institutional investors held Atea Pharmaceuticals (AVIR) as of Q2 2026, down from 127 in Q1 2026.
- Funds reported $276M of Atea Pharmaceuticals stock for Q2 2026, down 14% quarter-over-quarter.
- 19 funds opened new Atea Pharmaceuticals positions in Q2 2026 and 20 closed out, a net change of -1 holder.
- The largest Atea Pharmaceuticals buyer in Q2 2026 was Acadian Asset Management, an estimated $2.25M added.
- The largest Atea Pharmaceuticals seller in Q2 2026 was Jane Street, an estimated $2.25M sold.
Based on aggregated 13F filings for Q2 2026.